{"title": "Genetic testing: Not a one-and-done deal", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "Genetic testing: Not a one-and-done deal"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2018/09/180925140415.htm"}], "link": "https://www.sciencedaily.com/releases/2018/09/180925140415.htm", "summary": "A study that reviewed genetic testing results from 1.45 million individuals found that nearly 25 percent of 'variants of uncertain significance' were subsequently reclassified -- sometimes as less likely to be associated with cancer, sometimes as more likely.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "A study that reviewed genetic testing results from 1.45 million individuals found that nearly 25 percent of 'variants of uncertain significance' were subsequently reclassified -- sometimes as less likely to be associated with cancer, sometimes as more likely."}, "media_thumbnail": [{"url": "https://www.sciencedaily.com/images/2018/09/180925140415-large.jpg", "height": "200", "width": "300"}], "href": "", "published": "Tue, 25 Sep 2018 14:04:15 EDT", "published_parsed": [2018, 9, 25, 18, 4, 15, 1, 268, 0], "id": "https://www.sciencedaily.com/releases/2018/09/180925140415.htm", "guidislink": false}